Zydus Lifesciences

BSE: 532321 30 Sep 2025

Healthcare

₹ 1036.7

Zydus Lifesciences Limited specializes in Pharmaceuticals within the Healthcare sector.

Zydus Lifesciences

BSE: 532321 30 Sep 2025

Healthcare

₹ 1036.7

Zydus Lifesciences Limited specializes in Pharmaceuticals within the Healthcare sector.

Book Value

238.0

Dividend Yield

1.13%

Debt to Equity

0.13

Stock P/E

21.1

Market Cap

98,108 Cr

Zydus Lifesciences - Share Price & Details

Market Cap

₹98,108

High /Low

1,089 / 795.0

Stock P/E

21.1

Book Value

₹238.0

Dividend Yield

1.13

ROCE

24.3

ROE

₹21.2

Face Value

1.0

PEG Ratio

11.2

EVEBITDA

₹13.2

Debt

3,213

CMP / FCF

32.2

Debt to equity

₹0.13

NP Ann

4,673

High price all time

1,324

Piotroski score

₹7.0

Graham Number

493.0

No. Eq. Shares

101.0

Net CF

₹414

Net profit

4,711

Price to book value

4.1

Interest Coverage

₹29.7

Low price all time

25.5

Industry PE

33.0

Reserves

₹23,852

Free Cash Flow

₹5,116

Broker Recommendations

Date	Author	Type	Reco Price	Target Price	Potential	Source	PDF Link
13 Aug 2025	Prabhudas Lilladher	Buy	₹956.1	₹970	-1.8%	moneycontrol	View
13 Aug 2025	ICICI Securities	Hold	₹989.05	₹910	-7.4%	moneycontrol	View
26 May 2025	Deven Choksey	Buy	₹908	₹1,069	17.1%	moneycontrol	View
21 May 2025	ICICI Securities	Hold	₹882.75	₹910	2.2%	moneycontrol	View
21 May 2025	Prabhudas Lilladher	Buy	₹882.75	₹970	9%	moneycontrol	View
07 Feb 2025	KRChoksey	Buy	₹1,008.3	₹1,201	20.8%	moneycontrol	View
06 Feb 2025	Prabhudas Lilladher	Buy	₹1,008.3	₹1,050	4.1%	moneycontrol	View
06 Feb 2025	ICICI Securities	Hold	₹1,008.3	₹1,000	-0.2%	moneycontrol	View
13 Nov 2024	KRChoksey	Buy	₹963.6	₹1,201	21.9%	moneycontrol	View
13 Nov 2024	Prabhudas Lilladher	Buy	₹963.6	₹1,050	6.5%	moneycontrol	View
03 Oct 2024	Sharekhan	Buy	₹1,068.85	₹1,268	28.6%	moneycontrol	View
21 Aug 2024	KRChoksey	Buy	₹1,205.7	₹1,439	46%	moneycontrol	View
12 Aug 2024	Prabhudas Lilladher	Buy	₹1,249.7	₹1,305	32.5%	moneycontrol	View
21 May 2024	KRChoksey	Buy	₹1,088.45	₹1,186	20.7%	moneycontrol	View
20 May 2024	Prabhudas Lilladher	Buy	₹1,104.45	₹1,130	15%	moneycontrol	View
18 May 2024	Sharekhan	Buy	₹1,104.45	₹1,200	22.1%	moneycontrol	View
20 Mar 2024	Sharekhan	Buy	₹971.35	₹1,100	12%	moneycontrol	View
06 Mar 2024	KRChoksey	Buy	₹962.05	₹1,006	2.4%	moneycontrol	View
09 Jan 2024	Motilal Oswal	Hold	₹712.6	₹710	-27.7%	moneycontrol	View

Price Chart

Volume Chart

Peer Comparison

Stock	Total Income	Net Profit	Net Sales	EPS	Market Cap (in Cr)	P/E
FABINO ENTERPRISES LIMITED	NA	NA	NA	NA	5.09	84.8
Triochem Products Ltd.,	NA	NA	NA	NA	0
Zydus Lifesciences Limited	27454.0	3847.0	25883.0	3.82	98,108	21.1
LUPIN LTD.	57627.3	21280.7	57085.9	46.48	87688	23.7
FORTIS HEALTHCARE LTD.	4730.4	518.8	4330.3	0.69	70419	76.5

Peer Comparison Chart

About Zydus Lifesciences

Zydus Lifesciences Limited, with Security Code 532321, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.

Order Book

Latest News

Zydus Lifesciences shares in focus after Ahmedabad oncology unit gets USFDA EIR

(22 Sep 2025)

Zydus Lifesciences got a USFDA clearance upgrade for its Ahmedabad oncology plant, moving from OAI to VAI status after a June inspection—a...

Zydus gets USFDA EIR for Ahmedabad oncology injectable manufacturing facility

(22 Sep 2025)

Ahmedabad: Zydus has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for a GMP...

From IT stocks, Zydus Lifesciences to Oil India – Here are 10 stocks to watch today

(22 Sep 2025)

Track key stocks today including IT, Zydus Lifesciences, Oil India, and more amid major corporate developments—see which shares to watch!

Quarterly Table

Standalone Consolidated

Metrics	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Sales	2,579.3	2,955.7	2,159.3	2,371.3	3,332.4	4,160.2	2,620.6	2,515.9	5,819.6	2,588.3
Expenses	1,806.8	1,814.7	1,509.9	1,672.2	1,763.2	1,787.3	1,678.4	1,867.4	2,046.9	2,002.9
Operating Profit	772.5	1,141.0	649.4	699.1	1,569.2	2,372.9	942.2	648.5	3,772.7	585.4
OPM %	29.95%	38.6%	30.07%	29.48%	47.09%	57.04%	35.95%	25.78%	64.83%	22.62%
Other Income	47.4	82.4	534.5	106.8	352.5	106.6	326.7	77.5	185.4	157.1
Interest	85.0	89.7	90.9	103.9	106.2	115.4	95.9	97.2	155.4	137.6
Depreciation	119.9	121.2	124.9	127.7	130.6	130.6	133.7	131.6	128.0	130.0
Profit before tax	818.8	1,012.5	968.1	574.3	1,693.5	2,233.5	1,039.3	497.2	3,674.7	474.9
Tax %	-20.2%	-22.9%	-16.8%	-21.6%	-16.6%	-23.9%	-24%	-5.3%	-23.4%	19%
Net Profit	490.7	780.9	805.0	450.4	1,405.2	1,700.8	789.8	470.6	2,813.7	384.7
EPS in Rs	4.85	7.71	7.96	4.45	13.89	16.9	7.85	4.68	0	3.82

Metrics	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	4,362.3	5,010.6	5,139.6	4,368.8	4,505.2	5,533.8	6,207.5	5,237.0	5,269.1	6,527.9
Expenses	3,406.3	3,755.0	3,634.3	3,222.7	3,402.8	3,903.3	4,123.5	3,775.6	3,881.5	4,407.5
Operating Profit	956.0	1,255.6	1,505.3	1,146.1	1,102.4	1,630.5	2,084.0	1,461.4	1,387.6	2,120.4
OPM %	21.92%	25.06%	29.29%	26.23%	24.47%	29.46%	33.57%	27.91%	26.33%	32.48%
Other Income	38.5	-563.5	21.8	54.0	37.7	156.4	63.2	68.2	57.5	-139.0
Interest	32.8	27.7	18.1	8.7	19.8	34.6	32.2	25.1	32.0	76.6
Depreciation	181.6	178.6	179.8	184.2	194.8	205.3	215.3	233.6	229.0	237.9
Profit before tax	780.1	1,087.1	1,343.4	1,007.2	925.5	1,547.0	1,899.7	1,270.9	1,184.1	1,886.5
Tax %	-25%	-28.2%	-16.3%	-22.5%	-23.1%	-20.8%	23%	29.4%	15.2%	-25.3%
Net Profit	631.2	358.2	1,133.6	803.2	789.9	1,246.1	1,482.5	920.2	1,026.2	1,243.7
EPS in Rs	6.15	2.93	10.74	7.91	7.8	11.69	14.11	9.06	10.17	0

Shareholding Distribution

Shareholding Pattern

Compounded Data

Consolidated

Standalone

Compounded Sales Growth
10 Years:	11%
5 Years:	19%
3 Years:	24%
TTM:	40%

Compounded Profit Growth
10 Years:	16%
5 Years:	32%
3 Years:	74%
TTM:	68%

Stock Price CAGR
10 Years:	10%
5 Years:	21%
3 Years:	35%
1 Year:	-17%

Compounded Sales Growth
10 Years:	10%
5 Years:	10%
3 Years:	15%
TTM:	19%

Compounded Profit Growth
10 Years:	15%
5 Years:	26%
3 Years:	2%
TTM:	21%

Stock Price CAGR
10 Years:	10%
5 Years:	21%
3 Years:	35%
1 Year:	-17%

All Deals

Date	Stock	Party	Deal	Acq. Mode	Trans.	Quan.	Price	Value

Stock Mutual Funds Data

Order Book

News Date ▲▼	Headline ▲▼	Issuer Entity ▲▼	Issuer Type ▲▼	Order Size ▲▼	Time Period ▲▼
Loading company updates…

Loading technicals…

Moving Averages

Latest Close: — • Records Used: — • Last Trading Date: —

Simple Moving Averages (SMA)

Period	SMA Value	Status

Exponential Moving Averages (EMA)

Period	EMA Value	Status

Oscillators

Key Oscillators

latest calculation

Indicator	Value

Zydus Lifesciences

Zydus Lifesciences

Zydus Lifesciences - Share Price & Details

Broker Recommendations

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

About Zydus Lifesciences

Order Book

Latest News

Zydus Lifesciences shares in focus after Ahmedabad oncology unit gets USFDA EIR

Zydus gets USFDA EIR for Ahmedabad oncology injectable manufacturing facility

From IT stocks, Zydus Lifesciences to Oil India – Here are 10 stocks to watch today

Zydus’ Ahmedabad oncology plant gets positive USFDA compliance update

Zydus Lifesciences Receives Upgraded USFDA Classification for Oncology Facility

Zydus Lifesciences growth aided by acquisitions, but execution risks loom

Zydus Lifesciences Unit Debuts Pet Generic Drugs in US; Shares Trade Flat

Zydus Lifesciences launches generic drugs for cats and dogs

Zydus Lifesciences trades lower despite launching two generic drugs for pets; check details

Zydus Lifesciences arm launches generic drugs for cats and dogs in US

Zydus Lifesciences shares in focus on USFDA nod for canine drug

Are Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Investors Paying Above The Intrinsic Value?

Sun Pharma, Cipla, Dr Reddy’s, Zydus Lifesciences, Divi’s Labs, Torrent Pharma et al: Parsing through the pharma value chain

Stock Radar: Zydus Life stock breaks out from an inverse Head & Shoulder pattern; check target & stop loss

STOCKS IN NEWS: ACME Solar Holdings Ltd, Zydus Lifesciences, Aurobindo Pharma, Adani Power, Asian Energy Services, Ujjivan Small Finance Bank, Dee Development Engineers Ltd, Samvardhana Motherson International and others

Zydus Lifescience Share Price Dips After USFDA Observations | Stock Market Today

Zydus Lifesciences names Nitin D Parekh as President (Special Projects)

Zydus Lifesciences Appoints Nitin D. Parekh as President (Special Projects)

Zydus Lifesciences eyes US filing for chronic liver disease drug saroglitazar after successful PBC trial

Samir Desai, President-BU Biologics at Zydus Lifesciences, passes away

Zydus Lifesciences Announces Demise of Senior Management Personnel

F&O Radar| Deploy Broken Wing in Zydus Lifesciences to play bullish momentum for gains

Zydus Lifesciences Ltd soars 2.04%

Zydus Lifesciences gets four observations in USFDA inspection of Himachal Pradesh's Baddi plant

Zydus Lifesciences reports Q1 FY26 net profit at Rs. 1,466.8 Cr

Zydus Lifesciences Q1 Review: Systematix Maintains Hold, Revises Target Price — Heres Why

USFDA approves Zydus Lifesciences chronic idiopathic constipation drug Prucalopride

Zydus Lifesciences Limited Financial Performance for Q1 FY26

Zydus Lifesciences Q1 PAT up 5.9% on strong India, int'l formulations biz

Zydus Lifesciences Q1 net profit rises 3% to Rs 1,467 crore

Zydus Lifesciences Gains USFDA Nod for Diltiazem Hydrochloride Tablets

Zydus receives USFDA approval for constipation drug Prucalopride

Zydus Lifesciences gets NOC from Health Canada for ZDS-Varenicline tablets

Zydus Lifesciences Limited (ZYDUSLIFE) Expands into New Market - Get exclusive access to premium stock research

Can Zydus Lifesciences Limited (ZYDUSLIFE) Maintain Its Valuation - Remarkable growth

Zydus Lifesciences Limited (ZYDUSLIFE) Gets Regulatory Approval - Tremendous return on equity

Macro Trends and Their Impact on Zydus Lifesciences Limited (532321) - Lightning-fast capital gains

Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Zydus Life's plans for cancer biosimilar hit a legal hurdle

Zydus Lifesciences Limited (532321) Expands into New Market - Market-beating performance

Patent Infringement: Delhi High Court Restrains Zydus From Manufacturing Biologic Similar To 'Nivolumab'...

Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year

LIC, Hero MotoCorp, Divis, Pidilite, Zydus Life shares to turn ex-dividend next week

Zydus Lifesciences Ltd

Zydus Healthcare appoints Swati Dalal as Managing Director and Additional Director

Zydus Lifesciences Sees Significant Open Interest Surge Amid Active Market Participation

Swati Dalal joins Zydus Healthcare as MD

Zydus Lifesciences Shares Gain 1% on EIR from USFDA

ZYDUS LIFE RECEIVES USFDA EIR FOR GUJARAT FACILITY

Zydus Lifesciences shares in focus after USFDA issues EIR to Ankleshwar facility

Opening Bell: Sensex, Nifty to open flat ahead of CPI data; SBI, NTPC, Maruti, Wipro, Hindustan Copper, Zydus Lifesciences shares eyed

Zydus Life receives USFDA EIR for Gujarat facility

Stocks to Watch Today: Zydus Lifesciences, CE Info Systems Nazara Tech, Sterlite Technologies, HG Infra, Hindustan Copper, Angel One in focus on 12 June

Zydus Lifesciences gets all clear from US FDA for Gujarat API unit

Zydus Lifesciences Ltd spurts 0.24%, up for fifth straight session

Zydus Lifesciences Receives EIR from USFDA for API Manufacturing Facility at Dabhasa

Zydus Lifesciences Gets Clean USFDA Nod for Ankleshwar API Facility

Zydus Lifesciences to Enter the Global CDMO Business

Zydus Lifesciences To Subscribe To Equity Shares Of Torrent Urja 26

Zydus Lifesciences' Usnoflast receives USFDA fast track designation for ALS Treatment

Zydus Life says USFDA grants fast track designation for neurodegenerative disease treatment drug

Stock Picks: Sagar Doshi suggests Chennai Petroleum, LTIMindtree, Zydus Life shares to buy in a muted market today

USFDA grants Fast Track Designation to Zydus Usnoflast for amyotrophic lateral sclerosis

Zydus To Continue Mirabegron Sales

Zydus Lifesciences campaign on breast cancer gets 92 million views

Buy, Sell Or Hold: IndusInd, BSE, Zydus Life, ICICI Prudential, BHEL, Ashok Leyland — Ask Profit

Buy Zydus Lifesciences; target of Rs 1069: Deven Choksey

Zydus Lifesciences campaign drives breast cancer awareness through self-examination initiative

Stocks To Watch Today: Bharti Airtel, JSW Steel, Lupin, Inox Wind And Zydus Lifesciences